Riskpilot← Back to searchSign inGet full accessEmpros Pharma AB
ABActiveOrg 5569453862Nanna Svartz Väg 4Research and experimental development on natural sciences and engineering · NACE 7210Est. 20131-4 employees
Revenue 2024
SEK 8M
-83% vs 2023
EBITDA margin
-151.8%
-4% vs 2023
Equity ratio
99.2%
Financial strength
Net profit 2024
SEK -11,6M
-13% vs 2023
| Revenue | SEK 8M | -83% |
| EBITDA | SEK -12,1M | -4% |
| Net profit | SEK -11,6M | -13% |
| Total assets | SEK 129,6M | -12% |
| Equity | SEK 128,5M | -8% |
| Employees | — | — |
Legal name
Empros Pharma AB
Org number
5569453862
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
14 oktober 2013
Share capital
SEK 260 264
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas två i förening av ledamöterna Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget har till föremål för sin verksamhet att utveckla och marknadsföra läkemedel samt att bedriva därmed förenlig verksamhet.
Address
Nanna Svartz Väg 4
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 0 | 0 | 0 | 0 | 0 | 46 521 | 7 973 |
| Staff expenses | — | — | — | — | — | — | — | — | −4 121 | −2 746 |
| EBITDA | −3 434 | −3 274 | −6 092 | −7 229 | −5 064 | −6 578 | −11 869 | −9 213 | −11 687 | −12 105 |
| Depreciation & amort. | −310 | −310 | −310 | −310 | −0 | −0 | −0 | −0 | — | — |
| EBIT | −3 744 | −3 584 | −6 402 | −7 539 | −5 064 | −6 578 | −11 869 | −9 213 | −11 687 | −12 105 |
| Net financials | −9 | — | 4 | −4 | 1 | 1 | 2 | 36 | 1 358 | 470 |
| Profit before tax | −3 752 | −3 585 | −6 398 | −7 543 | −5 064 | −6 578 | −11 868 | −9 177 | −10 330 | −11 635 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 | −0 | — | — |
| Net profit | −3 752 | −3 585 | −6 398 | −7 543 | −5 064 | −6 578 | −11 868 | −9 177 | −10 330 | −11 635 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 7 589 | 42 273 | 34 725 | 26 760 | 59 041 | 53 948 | 57 656 | 76 665 | 147 266 | 129 574 |
| Equity | 6 049 | 39 764 | 33 367 | 25 825 | 57 822 | 52 393 | 56 203 | 71 890 | 140 133 | 128 498 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Short-term debt | 1 540 | 2 509 | 1 358 | 936 | 1 219 | 1 555 | 1 452 | 4 775 | 7 132 | 1 076 |
| Total debt | 1 540 | 2 509 | 1 358 | 936 | 1 219 | 1 555 | 1 452 | 4 775 | 7 132 | 1 076 |
EBITDA margin
-151.8%
This company
15.8%
Market median
-1061% vs market
20152024
Equity ratio
99.2%
This company
38.2%
Market median
+160% vs market
20152024
Return on equity
-9.1%
This company
18.4%
Market median
-149% vs market
20152024
Net profit margin
-145.9%
This company
8.1%
Market median
-1901% vs market
20152024
Asset turnover
0.06×
This company
1.12×
Market median
-95% vs market
20152024
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
JA Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
RJ Audit | Audit | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Flerie Invest AB | Company | 71.0% | 71.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Flerie Invest AB
Empros Pharma AB Board members of Empros Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Jan Arvid Söderhäll | Chief Executive Officer | 0 companies |
| Robert Jan Hasslund | Audit | 0 companies |
| Anne Bloch Thomsen | Board of Directors | 0 companies |
| Ulf Christian Bure Low Holmbäck | Board of Directors | 0 companies |
| Milan Zdravkovic | Board of Directors | 0 companies |
| Carl-Johan Spak | Board of Directors | 0 companies |
| Eugen Steiner | Chairman | 0 companies |
| Hans Olof Lennernäs | Board of Directors | 0 companies |
| Lars Åke Martin | Chairman | 0 companies |
| Mark Royston Quick | Board of Directors | 0 companies |